Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136029 · ClinicalTrials.gov registry record · Early Phase 1
Exercise and NO in HFrEF
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 68
- Enrollment target
NCT03136029: Completed Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT03136029 is a Early Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 68 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03136029, a Early Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Heart disease is the leading cause of death in the United States, accounting for one in every four deaths in 2010 and costing over $300 billion annually in health care, medication, and lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical syndrome that develops as a consequence of heart disease, now affects almost 6 million Americans. Within the VA Health Care System, HFrEF hospital admission rates continue to rise, and remain the number one reason for discharge from VA hospitals nationwide. Unfortunately, over one-third of all Veterans suffering from HFrEF die within two years of discharge despite optimized drug therapy, an unacceptably high number. This proposal is focused on how impaired muscle blood flow contributes to exercise intolerance in HFrEF, and on subsequently developing strategies for restoring exercise tolerance and slowing disease progression in this patient group. It is anticipated that knowledge gained from these studies will contribute to improved standard of care, quality of life, and prognosis in this VA patient group.
Primary Outcome
ultrasound Doppler
Interventions
- OTHER Exercise training
- DIETARY_SUPPLEMENT Antioxidant
- DIETARY_SUPPLEMENT Tetrahydrobiopterin (BH4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2025-07-31 |
| Phase | Early Phase 1 |
What the finished NCT03136029 record still lists
NCT03136029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 3 interventions - of which Exercise training is the first listed.
NCT03136029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03136029 about?
NCT03136029 is a clinical study titled "Exercise and NO in HFrEF". Heart disease is the leading cause of death in the United States, accounting for one in every four deaths in 2010 and costing over $300 billion annually in health care, medication, and lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical syndrome that develops as a c...
What is the current status of trial NCT03136029?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 68 participants. The study started on 2018-06-01. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT03136029?
The interventions under investigation include: Exercise training (OTHER), Antioxidant (DIETARY_SUPPLEMENT), Tetrahydrobiopterin (BH4) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03136029?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03136029's enrollment target sits among peer trials
68 357th of 2000 higher than 1,640 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI